Latest news
Exclusive BAC Article: MapLight Therapeutics; ML-007C-MA Schizophrenia EOP2 FDA Meeting, Topline Data 2nd Half 2027 AD Psychosis, Expansion Opportunities, And Catalysts (NASDAQ:MPLT) - Seeking AlphaSeeking Alpha · Wed, 29 Jul 2026 19:09:14 GMTMapLight Therapeutics, Inc. (MPLT) Discusses Top Line Results of Phase 2 ZEPHYR Study of ML-007C-MA in Schizophrenia - Slideshow (NASDAQ:MPLT) 2026-07-28 - Seeking AlphaSeeking Alpha · Tue, 28 Jul 2026 07:00:00 GMT